实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (4): 509-512.doi: 10.3969/j.issn.1672-5069.2025.04.008

• 病毒性肝炎 • 上一篇    下一篇

富马酸替诺福韦二吡呋酯联合当飞利肝宁胶囊治疗慢性乙型肝炎患者临床研究*

呙冬慧, 陈婷, 茅明   

  1. 210000 南京市 南京医科大学第四附属医院/南京市浦口医院药剂科
  • 收稿日期:2025-01-26 出版日期:2025-07-10 发布日期:2025-07-14
  • 通讯作者: 陈婷,E-mail:18005175608@163.com
  • 作者简介:呙冬慧,女,36岁,大学本科,主管药师。E-mail:13813034602@163.com
  • 基金资助:
    *南京医科大科科技发展基金面上项目(编号:2022NJMU260)

Clinical observation of tenofovir disoproxil fumarate and Dangfei Liganning capsule in treatment of patients with chronic hepatitis B

Guo Donghui, Chen Ting, Mao Ming   

  1. Department of Pharmacy, Fourth Hospital/ Pukou Hospital Affiliated to Nanjing Medical University, Nanjing 210000, Jiangsu Province, China
  • Received:2025-01-26 Online:2025-07-10 Published:2025-07-14

摘要: 目的 探讨应用富马酸替诺福韦二吡呋酯(TDF)联合当飞利肝宁胶囊治疗慢性乙型肝炎(CHB)患者的临床疗效。方法 2021年1月~2024年2月我院诊治的CHB患者97例,被随机分为对照组48例和观察组49例,分别给予TDF或TDF联合当飞利肝宁胶囊治疗观察48周。采用电化学发光法检测血清HBeAg和HBsAg水平,采用PCR法检测血清HBV DNA载量,采用化学发光法检测血清肝纤维化指标,采用ELISA法检测血清细胞因子水平,常规检测血清超氧化物歧化酶(SOD)、丙二醛(MDA)和一氧化氮(NO)水平。结果 在治疗48周末,观察组血清ALT和AST水平分别为(31.7±6.1)U/L和(39.5±7.3)U/L,均显著低于对照组【分别为(39.4±6.3)U/L和(45.3±6.1)U/L,P<0.05】;两组血清HBV DNA均转阴,但两组病毒载量及血清HBeAg和HBsAg水平无显著性差异(P<0.05);观察组血清透明质酸、层连蛋白和Ⅲ型前胶原水平分别为(186.3±8.2)ng/mL、(171.2±10.4)ng/mL和(158.5±14.7)ng/mL,均显著低于对照组【分别为(292.4±16.7)ng/mL、(230.5±12.7)ng/mL和(181.2±18.6)ng/mL,P<0.05】; 观察组血清白细胞介素-6(IL-6)、IL-8、肿瘤坏死因子-α(TNF-α)和转化生长因子-β1(TGF-β1)水平分别为(12.9±4.2)μg/L、(5.4±1.0)μg/L、(31.7±9.3)μg/L和(12.6±4.2)ng/L,均显著低于对照组【分别为(19.2±4.6)μg/L、(7.1±1.3)μg/L、(49.2±8.6)μg/L和(26.1±4.9)ng/L,P<0.05】;观察组SOD和NO水平分别为(116.3±17.2)U/mL和(44.2±6.5)μmol/L,均显著高于对照组【分别为(97.4±18.5)U/mL和(37.1±5.9)μmol/L,P<0.05】,而血清MDA水平为(7.1±1.8)nmol/L,显著低于对照组【(9.3±1.5)nmol/L,P<0.05】。结论 应用TDF联合当飞利肝宁胶囊治疗CHB患者可改善血清肝功能和纤维化指标,可能与协助抑制了细胞因子水平和氧化应激反应有关。

关键词: 慢性乙型肝炎, 替诺福韦, 当飞利肝宁胶囊, 治疗

Abstract: Objective The aim of this study was to investigate the clinical efficacy of tenofovir disoproxil fumarate (TDF) and Dangfei Liganning capsule, a herbal medicine compound, in the treatment of patients with chronic hepatitis B (CHB). Methods 97 consecutive patients with CHB were enrolled in our hospital between January 2021 and February 2024, and were randomly assigned to receive TDF in 48 cases in control, or to receive combination of TDF with the herbal medicine in 49 cases for 48 weeks. Serum HBeAg and HBsAg levels were detected by electrochemiluminescence and serum HBV DNA loads were quantitatively measured by real-time PCR. Serum hyaluronic acid (HA), laminin (LN), type III procollagen (PCIII) and type IV collagen (IV-C) levels were detected by chemiluminescence, serum interleukin(IL)-6, IL-8, tumor necrosis factor-α and transforming growth factor-β1 (TGF-β1) levels were assayed by ELISA, and serum superoxide dismutase (SOD), malondialdehyde (MDA), and nitric oxide (NO) levels were determined by xanthine oxidase, thiobarbituric acid and nitric acid reduction, respectively. Results By end of 48-week treatment, serum ALT and AST levels in combination group were (31.7±6.1)U/L and (39.5±7.3)U/L, both significantly lower than [(39.4±6.3)U/L and (45.3±6.1)U/L, respectively, P<0.05] in the control; serum HBV DNA in both groups transferred to negative, and there were no significant differences as respect to serum virologic and serologic markers in the two groups (P<0.05); serum HA, LN and PCⅢ levels in the combination group were (186.3±8.2)ng/mL, (171.2±10.4)ng/mL and (158.5±14.7)ng/mL, all much lower than [(292.4±16.7)ng/mL, (230.5±12.7)ng/mL and (181.2±18.6)ng/mL, respectively, P<0.05] in the control; serum IL-6, IL-8, TNF-α and TGF-β1 levels were (12.9±4.2)μg/L, (5.4±1.0)μg/L, (31.7±9.3)μg/L and (12.6±4.2)ng/L, all significantly lower than [(19.2±4.6)μg/L, (7.1±1.3)μg/L, (49.2±8.6)μg/L and (26.1±4.9)ng/L, respectively, P<0.05] in the control groups; serum SOD and NO levels were (116.3±17.2)U/mL and (44.2±6.5)μmol/L, both much higher than [(97.4±18.5)U/mL and (37.1±5.9)μmol/L, respectively, P<0.05], while serum MDA level was (7.1±1.8)nmol/L, much lower than [(9.3±1.5)nmol/L, P<0.05] in the control group. Conclusion Combination of TDF and Dangfei Liganning capsule has a better efficacy than TDF alone in the treatment of patients with CHB, which might be related to inhibition of liver fibrosis, body' s inflammatory reaction and oxidative stress.

Key words: Hepatitis B, Tenofovir disoproxil fumarate, Dangfei Liganning capsule,a herbal medicine compound, Therapy